Goldenwell Biotech (GWLL) EBIAT (2019 - 2025)
Goldenwell Biotech's EBIAT history spans 7 years, with the latest figure at -$7985.0 for Q3 2025.
- For Q3 2025, EBIAT rose 65.38% year-over-year to -$7985.0; the TTM value through Sep 2025 reached -$75118.0, up 39.83%, while the annual FY2024 figure was -$131498.0, 12.05% down from the prior year.
- EBIAT reached -$7985.0 in Q3 2025 per GWLL's latest filing, down from -$5220.0 in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$4584.0 in Q3 2022 to a low of -$920332.0 in Q4 2022.
- Average EBIAT over 5 years is -$73585.9, with a median of -$27536.0 recorded in 2024.
- Peak YoY movement for EBIAT: plummeted 16053.42% in 2021, then soared 97.74% in 2023.
- A 5-year view of EBIAT shows it stood at -$29541.0 in 2021, then tumbled by 3015.44% to -$920332.0 in 2022, then skyrocketed by 97.74% to -$20799.0 in 2023, then crashed by 32.39% to -$27536.0 in 2024, then skyrocketed by 71.0% to -$7985.0 in 2025.
- Per Business Quant, the three most recent readings for GWLL's EBIAT are -$7985.0 (Q3 2025), -$5220.0 (Q2 2025), and -$34377.0 (Q1 2025).